The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.
October 27th 2024
New ORIGIN trial data show atacicept may slow kidney decline in IgA nephropathy to rates seen with healthy aging, with notable reductions in Gd-IgA1 and UPCR.
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Multicomponent Intervention Fails to Improve Access to Kidney Transplantation
November 3rd 2023EnAKT LKD was conducted across 26 CKD programs in Ontario Canada, offering a multi-component intervention designed to target several barriers thought to prevent kidney transplantation and living donation - however, results showed no significant difference between the intervention and usual care groups.
Sparsentan Use Could Lower Risk of Kidney Failure, Death in FSGS
November 3rd 2023Although the DUPLEX trial missed its primary endpoint of eGFR slope in patients with FSGS, results point to greater reductions in proteinuria and in risk of kidney failure with sparsentan use relative to irbesartan—making its case for becoming a standard of care for the glomerular disease.
Urate-Lowering Therapy Could Also Lower Blood Pressure in Gout Patients
November 2nd 2023An analysis of the MIRROR trial from ASN Kidney Week 2023 details the effects of urate-lowering therapy on blood pressure among patients with uncontrolled gout receiving pegloticase plus methotrexate in the phase 4 trial.
FIDELITY Analysis Details Benefits of Early Albuminuria Reduction in CKD
November 2nd 2023Rajiv Agarwal, MD, MS, provides insight into an analysis from ASN Kidney Week 2023 detailing the effect of early albuminuria reduction on risk of adverse kidney and cardiovascular outcomes in people with T2D and chronic kidney disease.
ENVISION Trial: Sibeprenlimab Reduces 24-Hour UACR in IgA Nephropathy
November 2nd 2023Presented at ASN Kidney Week 2023, results of the ENVISION trial provide the latest insight into effects of sibeprenlimab in management of IgA nephropathy as the nephrology community awaits the results of its ongoing phase 3 trial.